Volumetric-Modulated Arc Therapy for Giant-Cell Tumor of Temporal Bone: An Illustrative Case Report.
Volumetric-Modulated Arc Therapy for Giant-Cell Tumor of Temporal Bone: An Illustrative Case Report.
复制标题
DOI：
10.1159/000526160
复制
发表时间：
2022-09
影响因子：
0.8
通讯作者：
Nagata, Yasushi
中科院分区：
文献类型：
--
作者：
Kubo, Katsumaro;Kenjo, Masahiro;Tominaga, Atsushi;Magaki, Takuro;Kawabata, Hideo;Miura, Hideharu;Nagata, Yasushi
颅骨巨细胞瘤极为罕见。手术是本病的主要治疗方法，但并不是所有病例都适合完全切除。在这篇报告中，我们报告了一例颞骨巨细胞瘤的临床特征，在放射治疗(RT)后显示良好的结果(VMAT)。患者为55岁男性，患有颞骨巨细胞瘤，首发治疗为手术治疗。初次手术三个月后，肿瘤复发，患者再次接受手术切除。虽然进行了第二次部分切除，但复发了。因此，在初次手术36个月后，进行了放射治疗。VMAT治疗剂量为54Gy1.8Gy1次。放疗开始后4个月肿瘤开始缩小，并缓慢逐渐缩小。在最后一次随访中，没有证据表明局部复发。目前还没有关于VMAT治疗颅骨巨细胞瘤的报道，也没有报道透露最近的放射治疗技术后的放射学细节。因此，本病例报告对描述颞骨骨巨细胞瘤VMAT术中及术后的治疗细节和治疗效果具有重要意义。在我们的颞骨巨细胞瘤病例中，使用VMAT的辅助放疗似乎显示了足够的局部控制益处，而没有严重的不良反应。
Giant-cell tumor of the skull is extremely rare. Surgery is the main treatment for this disease, but not all cases are suitable for complete resection. In this report, we present the clinical features of a case of giant-cell tumor of temporal bone that demonstrated good outcome after radiation therapy (RT) using volumetric-modulated arc therapy (VMAT). The patient was a 55-year-old man with giant-cell tumor of temporal bone who received surgery as the first treatment. Three months after the initial surgery, the tumor regrew, and the patient received surgical resection again. Although second partial resection was undergone, it regrew. Therefore, 36 months after initial surgery, RT was conducted. The prescribed dose was 54 Gy in 1.8 Gy fractions using VMAT. The tumor began to shrink from 4 months after the initiation of RT and kept shrinking slowly and gradually. At the last follow-up, there was no evidence of local recurrence. There was no report about VMAT for giant-cell tumor of the skull, and no report revealed the radiographic details after recent radiation techniques. Therefore, this case report was meaningful in describing the details and response during and after VMAT for giant-cell tumor of temporal bone. The adjuvant RT using VMAT seemed to demonstrate a sufficient local control benefit without severe adverse effects in our case with giant-cell tumor of temporal bone.
登录
查看更多内容
DOI：
10.1097/00003086-200102000-00026
发表时间：
2001-02-01
影响因子：
4.2
作者：
Cheng, CY;Shih, HN;Hsu, RWW
通讯作者：
Hsu, RWW
影响因子：
2.1
作者：
Tang, JY;Wang, CK;Huang, CJ
通讯作者：
Huang, CJ
影响因子：
3.9
作者：
Zorlu, F;Selek, U;Oge, K
通讯作者：
Oge, K
影响因子：
51.1
作者：
Chawla, Sant;Henshaw, Robert;Jacobs, Ira
通讯作者：
Jacobs, Ira
DOI：
10.1016/0360-3016(86)90346-9
发表时间：
1986-03-01
影响因子：
7
作者：
CHEN, ZX;GU, DZ;GU, XZ
通讯作者：
GU, XZ